Assessment of PTEN and PI3K status in primary breast cancer and corresponding metastases: is it worthwhile?

J Clin Oncol. 2011 Jul 10;29(20):2834-5; author reply 2835. doi: 10.1200/JCO.2011.35.1742. Epub 2011 Jun 13.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal / pharmacology*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / pharmacology*
  • Biomarkers
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / enzymology
  • Drug Resistance, Neoplasm*
  • Female
  • Humans
  • Lapatinib
  • PTEN Phosphohydrolase / metabolism*
  • Phosphatidylinositol 3-Kinases / metabolism*
  • Quinazolines / pharmacology*
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Biomarkers
  • Quinazolines
  • Lapatinib
  • Phosphatidylinositol 3-Kinases
  • PTEN Phosphohydrolase
  • PTEN protein, human
  • Trastuzumab